Where does Viking Therapeutics's cash flow data come from?

Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Viking Therapeutics VKTX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$472.34M-268%	-$359.64M-227%	-$237.39M-139%	-$171.55M-77.3%	-$128.24M-36.8%
Stock-based compensation	$39.81M+20.3%	$40.82M+37.4%	$37.9M+34.7%	$39.54M+67.4%	$33.08M+56.3%
Change in accounts payable	$59.48M+2,298%	$43.44M+1,786%	$4.16M—	-$5.59M—	$2.48M—
Change in accrued liabilities	——	——	——	——	——
Change in other assets	——	——	$17.97M—	$15.87M—	——
Non-cash operating lease expense	$405K+5.7%	$431K+24.6%	$447K+44.2%	$420K+41.9%	$383K+30.3%
Change in operating lease liabilities	-$515K-16.3%	-$505K-25.6%	-$517K-43.2%	-$483K-37.2%	-$443K-26.6%
Net cash from operating activities	-$340.33M-154%	-$278.69M-217%	-$224.58M-202%	-$152.54M-112%	-$133.99M-144%
Purchases of investments	$257.86M-65.6%	$418.04M-62.5%	$514.5M-52.1%	$643.04M-35.9%	$749.38M-26.4%
Proceeds from maturities/sales of investments	$590.19M-17.9%	$759.43M+35.6%	$786.86M+43.1%	$781.27M+77.3%	$719.05M+91.0%
Net cash from investing activities	$332.33M—	$341.39M—	——	——	——
Proceeds from issuance of common stock	——	——	——	——	——
Taxes paid for net share settlement	——	——	——	——	——
Net cash from financing activities	$88.17M+1,201%	$76.44M-87.5%	$2.34M-99.6%	$4.38M-99.3%	$6.78M-99.2%
Effect of exchange rate changes on cash	——	——	-$91K—	-$114K—	-$102K—
Net increase (decrease) in cash	$84.22M—	$143.19M—	$54.17M—	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$7.44M-57.7%	$9.28M-46.2%	$11.58M-27.3%	$14.53M+3.0%	$17.58M+65.3%
Amortization Of Financing Costs Equity Transactions	$32K-64.4%	$56K-40.4%	$80K-16.7%	$96K+29.7%	$90K+2.3%
Operating lease liabilities	-$515K-16.3%	-$505K-25.6%	-$517K-43.2%	-$483K-37.2%	-$443K-26.6%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$17.97M—	$15.87M—	——
Operating lease right-of-use asset amortization	$405K+5.7%	$431K+24.6%	$447K+44.2%	$420K+41.9%	$383K+30.3%
Operating Leases Interest Expense	——	——	$37K0.0%	$38K0.0%	$39K-2.5%
Proceeds from disposition of marketable securities and other investments	$590.19M-17.9%	$759.43M+35.6%	$786.86M+43.1%	$781.27M+77.3%	$719.05M+91.0%
Proceeds From Issuance Of At The Market Equity Offering Sales Agreement Net Of Fees	$85.58M—	$73.95M—	——	——	——
Proceeds from exercises of stock options and other stock issuances	——	——	——	——	——
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	——	-$91K—	-$114K—	-$102K—
Increase Decrease In Operating Lease Liability	-$515K-16.3%	-$505K-25.6%	-$517K-43.2%	-$483K-37.2%	-$443K-26.6%
Leased assets obtained in exchange for operating lease liabilities	——	$0-100%	$55.75K-66.7%	$111.5K0.0%	$167.25K+200%
Unpaid Deferred Initial Public Offering And Other Financing Costs	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Viking Therapeutics's cash flow data come from?: Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.